Drug intelligence / Profile preview

axicabtagene ciloleucel + mosunetuzumab + polatuzumab vedotin

Development stage: Unknown
Lead developer: Genentech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This combination therapy is a triple-agent regimen being evaluated in a Phase 2 clinical trial (NCT05260957) led by Dr. Lazaros Lekakis for the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma. The regimen integrates three distinct therapeutic modalities: axicabtagene ciloleucel (an anti-CD19 CAR-T cell therapy), mosunetuzumab (a CD20xCD3 bispecific T-cell engaging antibody), and polatuzumab vedotin (an anti-CD79B antibody-drug conjugate). By targeting three different B-cell antigens (CD19, CD20, and CD79B), the combination aims to overcome antigen escape and improve the durability of complete remissions in patients with aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma. The trial explores the use of mosunetuzumab and polatuzumab vedotin as consolidation therapy following CAR-T cell infusion.

Brand names: YescartaLunsumioPolivy
Other names: CAR-T with Mosunetuzumab and Polatuzumab for R/R Aggressive NHL

Targets

CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chainCD3 (T-cell surface glycoprotein CD3)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on axicabtagene ciloleucel + mosunetuzumab + polatuzumab vedotin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on axicabtagene ciloleucel + mosunetuzumab + polatuzumab vedotin.

Explore the full profile